Insider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells 80,000 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 80,000 shares of the firm’s stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $90.82, for a total value of $7,265,600.00. Following the completion of the sale, the insider now directly owns 117,560 shares in the company, valued at approximately $10,676,799.20. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Natera Trading Up 0.0 %

Shares of NASDAQ NTRA traded up $0.01 during trading on Wednesday, reaching $90.33. The company had a trading volume of 694,054 shares, compared to its average volume of 1,470,209. The company’s fifty day moving average price is $85.39 and its 200-day moving average price is $65.41. Natera, Inc. has a 12 month low of $36.90 and a 12 month high of $98.82. The stock has a market cap of $10.91 billion, a P/E ratio of -23.83 and a beta of 1.37. The company has a quick ratio of 3.96, a current ratio of 4.10 and a debt-to-equity ratio of 0.37.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.09. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. The firm had revenue of $311.11 million for the quarter, compared to analyst estimates of $300.38 million. As a group, research analysts expect that Natera, Inc. will post -2.35 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on NTRA shares. Sanford C. Bernstein raised Natera from a “market perform” rating to an “outperform” rating and set a $120.00 target price on the stock in a report on Friday, April 5th. BTIG Research raised their target price on Natera from $75.00 to $85.00 and gave the company a “buy” rating in a report on Friday, December 29th. Stephens reissued an “overweight” rating and set a $78.00 price objective on shares of Natera in a report on Tuesday, January 30th. Piper Sandler raised their price objective on Natera from $70.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, March 6th. Finally, The Goldman Sachs Group raised their price objective on Natera from $90.00 to $100.00 and gave the company a “buy” rating in a report on Monday. One research analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Natera has an average rating of “Moderate Buy” and an average target price of $86.40.

Institutional Investors Weigh In On Natera

A number of institutional investors have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC lifted its stake in shares of Natera by 28.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 720,160 shares of the medical research company’s stock valued at $45,111,000 after purchasing an additional 159,993 shares during the period. WCM Investment Management LLC lifted its stake in shares of Natera by 101.2% in the 4th quarter. WCM Investment Management LLC now owns 145,996 shares of the medical research company’s stock valued at $9,058,000 after purchasing an additional 73,419 shares during the period. Aigen Investment Management LP acquired a new position in shares of Natera in the 3rd quarter valued at about $223,000. Sei Investments Co. lifted its stake in shares of Natera by 33.4% in the 3rd quarter. Sei Investments Co. now owns 374,004 shares of the medical research company’s stock valued at $16,550,000 after purchasing an additional 93,556 shares during the period. Finally, Banque Pictet & Cie SA lifted its stake in shares of Natera by 7.3% in the 3rd quarter. Banque Pictet & Cie SA now owns 142,850 shares of the medical research company’s stock valued at $6,321,000 after purchasing an additional 9,755 shares during the period. Institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.